Novartis picks up bispecific antibodies from Xencor

June 29, 2016 8:45 AM

16 0

Novartis picks up bispecific antibodies from Xencor

Novartis has signed a collaboration and licensing deal with California biotech Xencor for access to its bispecific antibody technology and rights to develop and commercialise two of the latter's flagship experimental therapeutics.

The deal, reportedly potentially worth more than $2.4 billion, gives Novartis global rights (ex US) to XmAb14045, which is expected to begin clinical development for acute myeloid leukaemia in 2016, and XmAb13676, which should enter clinical development for B-cell malignancies also this year.

Also read: Early U.S. Cyber Monday sales point to 9 percent rise; fewer deals

Read more

To category page

Loading...